Get started
Author

Hiroki Goto

ORCID: 0009-0007-7143-2811
Observed ORCID: 0009-0007-7143-2811
OpenAlex ID: A5033241451
Abstract 7148: Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) treatment for HER2-positive (HER2+) metastatic colorectal cancer (mCRC) in DESTINY-CRC02 (DC-02)
2025 · Salvatore Siena, Kanwal Raghav, et al. · Cancer Research · 3
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2 -Amplified Metastatic Colorectal Cancer
2024 · Naoko Iida, Mitsuho Imai, et al. · Clinical Cancer Research · 2
Tumor and immune microenvironment remodeling with neoadjuvant trastuzumab deruxtecan in HER2-positive gastric cancer: Exploratory analyses from the phase 2 EPOC2003 study.
2026 · Akihito Kawazoe, Daisuke Takahari, et al. · Journal of Clinical Oncology
PDF
Figure S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2025 · Kimio Yonesaka, Junko Tanizaki, et al.
Figure S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer
2025 · Kimio Yonesaka, Junko Tanizaki, et al.
PDF
Abstract 424: Chromosomal instability leads to EGFR-TKI refractoriness via cGAS-STING activation in EGFR-mutated non-small cell lung cancer
2025 · Kimio Yonesaka, Takashi Kurosaki, et al. · Cancer Research
Data from Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer
2024 · Naoko Iida, Mitsuho Imai, et al.
Figure S3 from Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer
2024 · Naoko Iida, Mitsuho Imai, et al.
Figure S1 from Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer
2024 · Naoko Iida, Mitsuho Imai, et al.
Source data 1 from Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer
2024 · Naoko Iida, Mitsuho Imai, et al.
Figure S1 from Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer
2024 · Naoko Iida, Mitsuho Imai, et al.
PDF
Figure S2 from Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer
2024 · Naoko Iida, Mitsuho Imai, et al.
Figure S3 from Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer
2024 · Naoko Iida, Mitsuho Imai, et al.
Source data 1 from Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer
2024 · Naoko Iida, Mitsuho Imai, et al.
Figure S2 from Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer
2024 · Naoko Iida, Mitsuho Imai, et al.
Supplementary Data 1 from Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer
2024 · Naoko Iida, Mitsuho Imai, et al.
Data from Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer
2024 · Naoko Iida, Mitsuho Imai, et al.
Works count: 17
Citation count: 5
H-index: 2
I10-index:
Year
Topic
Type